mPharma pooled independent pharmacies' buying power to cut drug prices in Africa

mPharma was founded in 2013 by Gregory Rockson, Daniel Shoukimas and James Finucane to fix a perverse market: African pharmacies negotiate prices individually with suppliers, so the same medicine costs different amounts in different shops and stock runs out unpredictably.

Its mechanism is pooled procurement with vendor-managed inventory. mPharma manages drug supply for many pharmacies, negotiates bulk prices, and redistributes medicines as needed; pharmacists pay only for what they sell, which gives mPharma an incentive to keep prices low and shelves full.

The model attracted capital and expansion: by 2022 the company had raised $65 million, operated across African markets including Ghana, Nigeria, Kenya, Zambia and Zimbabwe, and was building Mutti community pharmacies around the supply network.

Aggregate demand before negotiating

Pooled demand gives a fragmented market the bargaining power of a chain.

Redistribution turns a stockout somewhere into a sale somewhere else.

Pay-for-what-sells aligns the intermediary with the pharmacy's margin.

Inventory data reveals demand well enough to plan purchases.

Where buyers are fragmented and suppliers are strong, the intermediary that aggregates demand captures the discount and the data.

A Skoll Foundation award in 2019 brought $1.5 million; a $35 million Series D in January 2022 funded data infrastructure and expansion, with the company aiming to make community pharmacies the first point of care across Africa.